Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Next Previous
X
Search
Trial Profile

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fadraciclib (Primary)
  • Indications Advanced breast cancer; B-cell lymphoma; Biliary cancer; Breast cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Cutaneous T-cell lymphoma; Endometrial cancer; HER2 negative breast cancer; Liver cancer; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Solid tumours; Squamous cell cancer; T-cell lymphoma; Uterine cancer
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Sponsors Cyclacel Pharmaceuticals

    • Most Recent Events

    • 25 Sep 2024 According to a Cyclacel Pharmaceuticals media release, updated safety and efficacy data from the 065-101 study of fadra has been accepted for presentation during the upcoming 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024, October 23-25, 2024).
    • 25 Sep 2024 According to a Cyclacel Pharmaceuticals media release, company announced that enrollment of 12 patients has been completed as per protocol in Cohort 8 (biomarker selected) of its Phase 2 stage. Enrollment of Cohort 5 in patients with T-Cell Lymphoma is continuing.
    • 04 Jun 2024 Results( As of January 31, 2024, n=45 ) evaluating the safety, pharmacokinetics, and efficacy of fadraciclib , presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top